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 To define the threshold for excess glucose variability (GV), one of the main feature of 
dysglycemia in diabetes. 
Research design and methods 
A total of 376 persons with diabetes investigated at the University Hospital of Montpellier, 
France, underwent continuous glucose monitoring. Participants with type 2 diabetes were 
divided into several groups: Groups 1, 2a, 2b and 3 (n=82, 28, 65 and 79, respectively) 
according to treatment (1) diet and/or insulin sensitizers alone, (2) oral therapy including an 
insulinotropic agent, DPP-4 inhibitors (group 2a) or sulfonylureas (group 2b) or (3) insulin. 
Group 4 included 122 with type 1 diabetes. Percentage Coefficient of Variation for glucose 
(%CV=[(SD of glucose)/(mean glucose)] x100) and frequencies of hypoglycemia (interstitial 
glucose < 56 mg/dL, 3.1 mmol/L) were computed. 
Results 
Percentages CVs (median [IQR],%) increased significantly (p<0.0001) from group 1 (18.1 
[15.2-23.9]) to group 4 (37.2 [31.0-42.3]). In group 1, the upper limit of %CV, which served 
as reference for defining excess of GV, was 36%. Percentages of patients with %CVs above 
this threshold in groups 2a, 2b, 3 and 4, were 0, 12.3, 19.0 and 55.7%, respectively. 
Hypoglycemia were more frequent in group 2b (p < 0.01) and groups 3 and 4 (p < 0.0001) 
when subjects with a %CV> 36% were compared to those with %CV≤ 36%. 
Conclusions 
A %CV of 36% appears to be a suitable threshold to distinguish between stable and unstable 
glycemia in diabetes since beyond this limit the frequency of hypoglycemia is significantly 




At present, there is incontrovertible evidence that chronic hyperglycemia is a key player in the 
pathogenesis of all related-diabetes complications, both in type 1 [1,2] and type 2 diabetes 
[3,4]. However glucose variability (GV) and hypoglycemia, the second and third components 
of the “glucose triumvirate”  [5] may also be considered as risk factors for vascular 
complications in diabetes mellitus. Excess GV is usually associated with increased risk of 
hypoglycemic events necessitating a global therapeutic approach aimed at avoiding 
hypoglycemic episodes whilst maintaining the HbA1c levels within an individually defined 
target range according to patient-centered therapeutic strategies [6]. HbA1c-based strategies 
are limited by the fact that they do not integrate the GV and at present the role of GV on the 
development and progression of cardiovascular diseases remains a subject of controversy [7-
9]. The proof-of-concept FLAT-SUGAR randomized interventional study [10], was designed 
to identify a difference in GV between two groups of insulin-treated subjects with type 2 
diabetes. These participants were assigned either to continue basal-bolus insulin after a run-in 
period or to replace the premeal short-acting insulin analog with mealtime dosing of exenatide 
while continuing the basal insulin glargine. The secondary outcome of the FLAT SUGAR 
trial was to test the hypothesis that improvements in GV in insulin-requiring diabetes can 
exert beneficial effects on markers of cardiovascular risk. As hypoglycemic episodes and GV, 
concomitantly or separately, are potential causative factors for cardiovascular events, the 
question arises as how to separate the patients with unstable diabetes from those considered 
stable. Therefore, we should identify a threshold for the amplitude of GV below which the 
risk of hypoglycemia would be negligible. Consequently we analyzed continuous glucose 
profiles from groups of patients with type 1 or type 2 diabetes to gain further insight into this 
conundrum. Data from those subjects treated only with diet alone or with the addition of 
insulin sensitizers, which represent little or no risk of hypoglycemia (reference group), were 
used to determine the upper level of GV to define the threshold between stable and unstable 
diabetes. Patients from the other groups were compared to the reference group to determine 
the proportion of exaggerated glycemic fluctuations and frequency of accompanying 
hypoglycemic episodes. This aspect is crucial when it comes to healthcare providers in order 
to achieve and sustain optimal glycemic control by achieving and maintaining GV within a 
reasonable range and with minimal risk of hypoglycemia. Presently there are clear 
recommendations for the management of chronic hyperglycemia with most organizations 
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recommending a target HbA1c level of 7% (53 mmol/mol) [6,11]. However, to date there are 
no recommendations provided for GV, which this present study is designed to address. 
RESEARCH DESIGN AND METHODS  
Study design and participants 
A total of 376 persons with either type 1or type 2 diabetes were included in the study between 
2003 and 2012. All participants regularly attended the outpatient clinic of the University 
Hospital of Montpellier (France) and were entered consecutively without any selection based 
on HbA1c, age, sex, duration of diabetes or diabetic complications. The study was 
observational in design and the data were retrospectively analyzed. Out of the 376 patients 
included in this study, 82 type 2 diabetes were treated with diet and/or insulin sensitizers 
alone. These patients, referred to as group 1, were selected to serve as reference for stable 
glucose homeostasis diabetes. The rationale for this choice was based on two main principles 
and observations. Firstly, patients treated with insulin sensitizers alone correspond usually to 
persons who are at an early stage in the natural history of type 2 diabetes. Such patients have 
usually relatively small glucose fluctuations that are mainly due to postprandial excursions 
and which remain relatively constant across the HbA1c spectrum [12]. Secondly, this group 
corresponds to patients in whom the risk of hypoglycemic episodes is also very low or even 
absent [13] and who, consequently, have a low likelihood that glycemic variability be 
compounded by glycemic rebounds due to correction of symptomatic hypoglycemia. Type 2 
diabetic patients treated with oral hypoglycemic agents known to have insulinotropic effects 
were excluded from the reference group even though DPP-4 inhibitors stimulate the 
endogenous insulin secretion in a glucose-dependent manner [14], which theoretically 
excludes the risk for hypoglycemic events.  
Besides the reference group, other groups of patients were selected by types of diabetes and 
categories of antidiabetic treatments. Their detailed characteristics are reported later at the 
beginning of the results section. 
Considered as a whole, all patients were stable on their respective treatment regimens for at 
least three months prior to the investigations. The 376 patients included in the present study 
were selected among a total population of 559 subjects with type 1 or type 2 diabetes who 
underwent 3-day ambulatory continuous glucose monitoring (CGM). Criteria of exclusion 
from the initial screened list of potential participants included those who had experienced a 
recent illness or been treated with steroids during the 3-month period preceding the 
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investigation. In addition, exclusion criteria from the final analysis were unexpected 
disruptions in the glucose monitoring or insufficient number of capillary tests on whole blood 
glucose for the calibration of the CGM (four tests were required daily for this purpose). 
Acceptable calibration meant an accuracy criterion with a correlation coefficient > 0.79. All 
the investigations were routinely performed in the diabetic outpatient clinic of the University 
Hospital of Montpellier (France) and were in accordance with the Helsinki Declaration [15]. 
As the study was observational in design, each participant gave an oral informed consent in 
accordance with European directives that require no approval from an ethics committee due to 
the non-interventional design of the study [16]. 
Clinical investigations and laboratory determinations 
All participants underwent ambulatory continuous glucose monitoring (CGM) for 3 
consecutive working days, avoiding the weekend, using the same technology during 2003 to 
2012 (i.e. second-generation MiniMed system [Medtronic, Northridge, CA]). The sensor was 
inserted on day 0 (before 1200 h) and removed on day 3 at the same time point as on day 0.  
Chronic hyperglycemia was assessed on study day 0 based on HbA1c levels, determined 
using a high-performance liquid chromatography assay [17] (Menarini Diagnostics, Florence, 
Italy).  
Analysis of the data from the CGM 
CGM was used to calculate the mean 24-h glucose concentration and SD (standard deviation 
around the mean glucose value). GV was determined using the percentage Coefficient of 
Variation for glucose (%CV) obtained from the following computation: [(SD of 
glucose)/(mean glucose)] x 100. The percentage Coefficient of Variation for glucose is 
probably one of the most reliable markers to assess the amplitude of GV as it is adjusted for 
the mean glucose value and does not depend on this parameter [18,19,20]. Furthermore, it is 
well known that all parameters described for assessment of GV are highly intercorrelated [21-
23] and some investigators have established that the %CV is a valid GV index especially 
when used in combination with other more complex metrics of glycemic control [22]. It 
should also be appreciated that healthcare professionals by reading simple metrics such as the 
mean 24-h glucose value and the SD provided by CGM systems and printed on the files 
associated with traces of the glycemic profiles can easily calculate the %CV. For the 
aforementioned reasons and as the aim of our study is essentially pragmatic in its objectives, 
we have deliberately not studied the more sophisticated indices of GV such as the MAGE 
 6 
(Mean Amplitude of Glycemic Excursions), the MODD (Mean Of Daily Differences), the 
CONGA (Continuous Overlapping Net Glycemic Action), the LBGI (Low Blood Glucose 
Index) and others  [24-26]. Many of these indices have been widely described and more 
commonly used in type 1 diabetes and not type 2 diabetes [23]. In addition, some of these 
metrics such as the LBGI for hypoglycemia [27] are more oriented towards the risk analysis 
of adverse events relevant to GV than towards the specific assessment of GV. 
Based on two validated 24-h glycemic profiles on study days 1 and 2, the SDs, 24-h mean 
glucose values and %CVs were averaged for these two consecutive days. The data recorded 
on day 0 were excluded from the analysis in order to avoid any bias due to glucose 
stabilization between the sensor and the interstitial fluid during the first hours after insertion 
of the device. Calculations were made at 5 minute-time intervals. In each group, the relative 
frequency for distributions of %CV values was tested for normality using the Shapiro and 
Wilk test [28]. However, as this test failed to demonstrate a unimodal, non-skewed Gaussian 
distribution, the analyses were performed using non-parametric statistics: medians and 
interquartile ranges. As mentioned above, group 1 patients were taken as reference for ‘stable’ 
diabetes, in view of the small/absent risk of hypoglycemia and limited glucose fluctuations. 
The upper limit of %CVs in group 1 (%CVmax1) was referred to as the threshold between 
stable and unstable glycemic control. In all groups, including group 1, the presence of 
hypoglycemia based on the 24-h glucose profile was considered as a whole. When applicable, 
i.e. when some individuals of a given group had %CV greater than the %CVmax1, the patients 
of this group were tested for the presence of hypoglycemia after they had been divided into 2 
subgroups according to whether %CVs were above or below the %CVmax1 determined in the 
reference group. Hypoglycemia was defined as 3 consecutive interstitial glucose levels < 56 
mg/dL (3.1 mmol/L) with time spent ≥ 15min. Hypoglycemic episodes were reported by 
reading the 24-h glucose profiles.  
Additional calculations and statistical analysis 
Except for hypoglycemia, comparisons between groups or subgroups were made using the 
non-parametric Kruskall-Wallis or the Mann and Whitney tests as appropriate. In groups 2a, 
2b, 3 and 4, percentages of %CVs above the %CVmax1 were calculated. Comparisons between 
percentages in the different groups were made using the Chi square or exact Fisher test. The 
number of hypoglycemic episodes expressed as number per patient-day was compared 
between groups and between subgroups exhibiting stable (%CV ≤ %CVmax1) and unstable 
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(%CV > %CVmax1) glucose homeostasis. For that purpose, Poisson regression models were 
fitted after plotting the number of hypoglycemic episodes as dependent variable and groups of 
patients as explanatory variable. Simple correlations between either SD or %CV and mean 
glucose values were calculated using the Spearman rank test. All p values were considered 
significant when < 0.05. Data were analyzed using the R software version 3.2.3. 
RESULTS 
Of the 376 persons who were included in the present study, 122 had type 1 diabetes and 254 
type 2 diabetes, which were further divided into several groups. Among those with type 2 
diabetes, 82 (group 1) were on either dietary measures alone (n = 8) or on treatment 
combining diet with insulin sensitizers (metformin and/or glitazones, n = 74), 93 (group 2) 
received dual or triple oral antidiabetic therapy combining one or two insulin sensitizers with 
at least one insulinotropic agent, either a DPP-4 inhibitor (sitagliptin or vildagliptin, subgroup 
2a, n = 28) or a sulfonylurea (glimepiride or glibenclamide, subgroup 2b, n = 65). Finally 79 
(group 3) were on insulin treatment prescribed as either basal insulin alone (n = 33) or basal-
bolus insulin regimens (n = 46). The 122 subjects with type 1 diabetes (group 4) were treated 
with either basal-bolus regimens delivered as multiple injections (n = 97) or by subcutaneous 
insulin pumps (n = 25). Demographic characteristics of patients, treatment categories and 
laboratory data in the different groups are shown in table 1. 
Comparison of parameters of glycemic control in the different groups 
The median HbA1c levels were significantly lower (p<0.0001) in orally treated groups (1, 2a 
and 2b) than in the insulin-treated groups (3 and 4).The SDs (median [IQR], mg/dL) steadily 
and significantly (p<0.0001) increased from group 1 (25 [19-33]) and group 2a (23 [19-28]) 
to group 4 (58 [44-73]). Similar results were observed for %CVs (median [IQR],%) that 
increased from 18.1 [15.2-23.9] in group 1 and 18.6 [16.6-22.4] in group 2a to 37.2 [31.0-
42.3] in group 4 (p<0.0001). Furthermore in group 3 the %CVs (median [IQR]) were 
approximately the same in patients on basal insulin (29.7 [23.1-35.1], n = 33) as in those on 
basal-bolus insulin regimen (26.9 [19.5-34.3], n = 46). 
Distributions of percentage Coefficients of Variation for glucose (%CV) in the different 
groups  
Histograms of relative frequency distributions for %CVs are given in figure 1.  In the 
reference group (group 1), the upper limit of the distribution of %CV was found to be of 36%, 
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which was adopted as reference threshold (%CVmax1) to separate stable from unstable 
glycemia. In the particular setting of our population, percentages of patients exhibiting %CVs 
above this upper limit were found to be of 0%, 12.3%, 19.0% and 55.7% in groups 2a, 2b, 3 
and 4, respectively. Differences between percentages were statistically significant (p < 
0.0001) when group 4 was compared to groups 2a, 2b and 3. Furthermore by pooling all 
subjects with type 2 diabetes without any hypoglycemia (n = 154), the upper limit of 
distribution of %CV was 38%, i.e. a value quite similar to that observed in the reference 
group (36%). 
Number of hypoglycemic episodes in the different groups 
The results are represented in figures 2 and 3. Groups 1 (reference group) and 2a patients 
(DPP-4 inhibitor + insulin sensitizers) were almost devoid of hypoglycemia. Hypoglycemia 
occurred in all the other groups and were more prevalent in type 1 diabetic patients (p < 
0.0001, group 4 vs groups 1, 2a, 2b and 3) (figure 2). As illustrated in figure 3, the frequency 
of hypoglycemia was significantly greater in the subgroups with a %CV > 36% than in the 
subgroups with values ≤ 36% (p< 0.01 in group 2b; p< 0.0001 in groups 3 and 4). Medians of 
24-h mean glucose values between subgroups with a %CV> or ≤ 36% were slightly different 
in group 3 (p=0.018) but not in groups 2b and 4 (figure 3). 
 Relationships between parameters of glucose variability and 24-h mean glucose 
concentrations  
In the study population considered as a whole (n = 376), SD correlated positively and 
significantly with 24-h mean glucose concentration (rhô = 0.50, p < 0.0001) while the %CV 
did not (rhô = 0.04, p = 0.42). 
CONCLUSIONS 
There are two main messages emanating from the present study.  Firstly, GV represented by 
the %CV was greater in the subjects with type 1 than in type 2 diabetes and there was a 
steadily increasing glucose variability across the continuum of type 2 diabetes from those on 
diet with or without insulin sensitizers and those treated with DPP-4 inhibitors to those 
receiving sulfonylureas and finally those subjects on different insulin regimens. Secondly, a 
threshold for %CV of 36% permits discrimination between those with stable or unstable 
glucose homeostasis. However, one of the remaining questions is to know whether GV should 
be assessed in diabetes care as we are still awaiting the findings from interventional studies 
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designed to evaluate whether lowering GV to within near normal limits can prevent the 
development and/or progression of diabetic complications. However, the recent publication of 
the results of the FLAT-SUGAR Trial [29] does not provide any compelling evidence that 
reduction of GV can result in improvements of certain cardiovascular bio-markers such as 
CRP, interleukin 6 or urinary prostaglandin F2, representing the inflammatory or oxidative 
stress status [30].  
Nevertheless, even though the relationship between GV per se and adverse cardiovascular 
outcomes has not been established, it remains that increased glucose fluctuations can play a 
consistent role in precipitating hypoglycemia [26,31]. Highly significant correlations have 
been observed in persons with diabetes treated with insulin between the percentage 
coefficients of glucose variation (%CV) and risk of hypoglycemia [20,22]. Fabris et al 
reported a correlation coefficient as high as 0.81 between the %CV and percentage of values 
below a glucose target set at 70-180 mg/dL (supplementary data) [22]. In the present study, 
we similarly found a relationship between the %CV and frequency of hypoglycemia, which 
was significantly greater in subjects who had a value above 36% than in those who were 
below this threshold. It should be noted that this evaluation was mainly conducted to validate 
our primary objective, i.e. the determination of the threshold between low and high glucose 
variability in persons with diabetes mellitus in the particular setting of our study. Bringing all 
these observations together, healthcare professionals should be encouraged to achieve a 
lowering of GV especially when patients are affected by exaggerated glucose oscillations. 
Such an approach requires the definition of an upper limit of GV in order that clear 
instructions can be provided to both patients and healthcare providers. Therefore, indices 
recommended for the GV assessment must be easily accessible and computable by any 
healthcare professional. Consequently, determining the %CV appears to be more suitable than 
the other more complex indices mentioned above [18,19,24]. According to our results, 
obtained by analyzing the frequency distribution of GV in the reference group, a threshold for 
%CV of approximately 36% seems appropriate for this purpose. A few years ago, basing his 
statement on personal observations Hirsch proposed as ideal target for glycemic variability a 
SD calculated from the following formula: SD x 3<Mean Glucose, i.e. a %CV < 33% [32]. 
More recently, Rodbard [19] found that by stratifying insulin-treated patients (both type 1 and 
2 diabetes) according to whether the %CV corresponded to the 25th, 50th, and 75th 
percentiles of the data distribution, a cut-off value between high (fair and poor) and low (good 
and excellent) of 36% can be set. This threshold 
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is exactly the same as that observed in our study. However, one of the strength of our 
approach was to show that the distribution of %CV was different in subjects with type 1 
diabetes and in those with type 2 diabetic on insulin treatment as indicated in figure 1. 
Reverting to the Rodbard’s study [19] no difference was found in GV between type 1 and 
insulin-treated type 2 diabetes. However it should be noted that all patients were on basal-
bolus insulin regimens while, in our study, approximately one half of the subjects with type 2 
diabetes treated with insulin were on once-daily basal insulin alone. This difference in insulin 
regimens could explain the apparent discrepancies between the findings in the two studies. 
Even though the rationale for the selection of the upper limit of %CV in our reference group 
can be debated, this choice seems to be a posteriori validated by several observations. Firstly 
the upper limit of distribution in the reference group (36%), i.e. in type 2 diabetic patients 
treated only with diet and/or insulin sensitizers was approximately the same as that observed 
by using another approach that consisted to assess this upper limit after pooling in a single 
group all patients with type 2 diabetes without any hypoglycemia. Secondly, we observed a 
three to nine-fold increase in the frequency of hypoglycemia when adopting this threshold 
across the various groups of patients included in this study. In the group of persons with type 
2 diabetes treated with DPP-4 inhibitors, no patient was above the threshold of 36%. In 
contrast, 12.3% of type 2 diabetes subjects treated with sulfonylureas were above this 
threshold of 36% and thus defined as unstable with a risk of hypoglycemia three times greater 
than in those below this threshold. Also, when utilizing this threshold of 36%, the percentage 
of insulin-treated patients designated as unstable was found to be as high as 19.0% and 55.7% 
in type 2 and type 1 diabetes, respectively. These observations were associated with the fact 
that in the present study the %CV progressively increased across the spectrum of diabetes 
from non-insulin-treated type 2 diabetes to insulin-treated type 2 diabetes and finally to type 1 
diabetes. Our results are in agreement with those reported by Khonert et al [23] and by 
Midyett et al presented at the 76th meeting of the American Diabetes Association held on 
June 2016 [33].  In addition our findings indicate that GV is markedly increased in persons 
with diabetes irrespective of the group considered when compared to non-diabetic individuals 
[34]. These observations suggest that disease progression is reflected in worsening of GV 
compounded by the necessary escalation of treatment. However, it should be noted that there 
is no difference between patients with type 2 diabetes treated with basal insulin when 
compared with those on basal-bolus regimen. 
Employing continuous glucose monitoring raises the question as to whether abnormally high 
glucose variability remains under diagnosed when using self monitoring of blood glucose, 
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especially in patients with type 2 diabetes treated with insulinotropic agents (sulfonylureas) 
and/or insulin therapy. Is there an argument in favor of a broader utilization of CGM data for 
detecting silent hypoglycemic events in such patients at least in those who are considered 
“vulnerable” and prone to hypoglycemia? 
As frequency of hypoglycemic episodes might also result from lower mean glucose value 
[26,31,35,36] this parameter should be taken into account in interpreting our results. In the 
present study, the potential impact of a low mean glucose concentration on the incidence of 
hypoglycemia can be ignored in persons with type 1 diabetes, because the 24-h mean glucose 
values were similar in this group of patients, irrespective of the magnitude of the GV based on 
a %CV of >36% or ≤ 36%. Furthermore, the %CV has the main advantage of not being 
dependent on the mean glucose concentration [18,19].  
The present work has a number of limitations. Firstly all measurements were made using an 
older generation of CGM but in our group of type 2 diabetic patients treated with insulin the 
means of %CV were approximately the same as the values observed at baseline in the 
population of the FLAT-SUGAR study [10,29] using a newer generation of CGM (DEXCOM 
SEVEN PLUS or G4). In addition all assessments of GV were limited to the monitoring of 
24-h glycemic profiles on two consecutive days and the determination of a single parameter.  
In the future longer monitoring with newer generations of devices and other markers of GV 
may be required to confirm our findings. However, utilizing CGM is never devoid of 
between-and within-setting variations [37]. Finally the interstitial glucose value of 56 mg/dL 
(3.1 mmol/L), which was selected as threshold for hypoglycemia in the present study, is a 
compromise between the technical limitation of CGM and the definition of hypoglycemia that 
was set at 70 mg/dL by the ADA in 2005 [38]. With the older technology of CGM used in the 
present study, the monitoring system underestimated the real glucose value [7,39,40]. 
Throughout the time course of hypoglycemia, i.e. in non-steady state conditions, the relative 
difference between sensor readings and plasma glucose values varied between 0 and 20% 
[39]. In steady state conditions absolute differences of – 12 mg/dL [40] to – 19 mg/dL [7] 
were observed between interstitial glucose and the glucose value using the reference method 
when, like in the present study, the CGM was calibrated against capillary glucose 
concentrations. As it has been established that capillary and interstitial glucose values were 
underestimated at a similar extent when compared with the reference method [40], and as we 
have chosen to set the plasma-to-interstitial gradient at its upper limit of – 20%, a 
subcutaneous value of 56 mg/dL (3.1 mmol/L) corresponded approximately to a plasma 
glucose concentration of 70 mg/dL (3.9 mmol/L). 
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Despite these limitations, and in summary, it now seems timely to include targeting glucose 
variability to the assessment of chronic hyperglycemia utilizing HbA1c [11]. Our findings 
indicate that setting a threshold for GV based on %CV of blood glucose at 36% could be used 
to discern between stable and unstable glucose homeostasis. A more graded scale such as low, 
fair, moderate or high would also be welcome. The proposed threshold of 36% is supported 
by the observation of an increased frequency of hypoglycemia in patients with type 1 diabetes 
and in those with type 2 diabetes on insulin therapy as soon as this threshold is transgressed. 
Finally, we strongly recommend that more consideration be given to the assessment of GV, 
primarily in type 1 diabetes, but also in type 2 diabetes when on insulin treatment or more 
generally when any medication with a risk of hypoglycemia is implemented. 
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Legends of figures 
 
Figure 1: Histograms of relative frequency distributions for Coefficients of Variation for 
glucose (%CVs) in the 5 groups of persons with either type 2 (groups 1, 2a, 2b, and 3)  or 
type 1 diabetes (group 4).  
The upper limit of the distribution of %CV (%CVmax1 = 36%) in group 1 (no insulinotropic 
agent) is taken as reference to discern stable from unstable diabetes. In the 4 other groups the 
percentages of patients above this threshold value of 36% are indicated as appropriate in the 
corresponding panels. 
Figure 2: Incidence of hypoglycemia (upper panel) and results of 24-h mean interstitial 
glucose values given as medians with interquartile ranges, 10
th
  and 90
th
 percentiles (lower 
panel).  
Statistical comparisons between  groups 1, 2a, 2b, 3 and 4: (a) group 2b vs 1 and 2a (p < 
0.01); (b) group 3 vs 1 and 2a (p < 0.001); (c) group 4 vs 1, 2a, 2b and 3 (p < 0.0001); (d) 
group 3 vs 1,2a and 2b (p < 0.0001); (e) group 4 vs 1 and 2a (p < 0.0001) and (f) group 4 vs 
2b (p< 0.01). 
Figure 3: Incidence of hypoglycemia (upper panel) and results of 24-h mean interstitial 




 percentiles (lower 
panel) when patients of each group were divided into 2 subgroups according to whether % 
CVs were > 36% or ≤ 36%.  




 Table 1: Demographic, clinical and laboratory characteristics of the patients enrolled in the different groups 
Groups of patients Type 2 treated Type 1 P 
 Without any 
insulin 
secretagogue 











 (Group 1) (Group 2a) (Group 2b) (Group 3) (Group 4  
N°of subjects N = 82 N = 28 N = 65 N = 79 N =122  
Age (years) 63  57  62 64 52  <0.0001 
 [56-67] [55-65] [57-69] [59-73] [43-72]  
Men/women (n) 52/30 17/11 49/16 38/41 67/55  
BMI (kg/m
2
)  30.2  29.9 28.7  29.6  24.2 <0.0001 
 [27.5-33.6] [27.0-33.6] [24.3-33.2] [25.2-33.3] [22.4-27.3]  
Diabetes duration 
(years) 
4 [2-8] 4.5 [1-8] 10.0 [4-17] 18 [11-28] 28 [20-35] <0.0001 
Diabetes treatment 
(%) 
      
Any insulin sensitizer 90.2 100 100 50.6 0  
Any DPP-4 inhibitors 0 100 0 0 0  
Any Sulfonylurea 0 0 100 53.2 0  
Type of insulin 
treatment if any 
      
- Basal regimen    41.8 0 <0.0001 
- Basal-bolus regimen    58.2 79.5  
- Pump therapy     20.5  
HbA1c (%) 7.1  6.8  7.6 8.6  8.0  <0.0001 
 [6.8-7.7] [6.4-7.0] [7.1-8.6] [8.0-9.2] [7.4-8.9]  
HbA1c (mmol/mol) 54 51 60 70 64  
 [51-61] [46-53] [54-70] [64-77] [57-74]  
24-h mean glucose 
concentration (mg/dL) 
137  120  139  175  154  <0.0001 
 [123-151] [113-131] [125-165] [153-207] [136-198]  
SD around the mean 
glucose value (mg/dL) 
25  23  33  47  58  <0.0001 
 [19-33] [19-28] [24-43] [36-61] [44-73]  
Percentage Coefficient 
of Variation for 
glucose (%CV) 
18.1  18.6  23.7  27.8  37.2 
 
<0.0001 
 [15.2-23.9] [16.6-22.4] [16.8-29.0] [21.2-34.4] [31.0-42.3]  
All data are reported as medians and interquartile range [IQR]. Comparisons were made using non-parametric 
statistics and are indicated when significant (p < 0.05). 
 
